About 1 in 10 adults aged 70 or older may be eligible for anti-amyloid therapy, finds the first population-based study to use ...

Alzheimer’s Disease research is advancing with developments like Roche’s new biomarker blood test. Yet 98% of AD clinical ...

A small study shows cognitive improvements in patients with AD following treatment with an in-home gamma sensory stimulation ...

For over a century, Alzheimer's disease (AD) has been considered irreversible. Consequently, research has focused on disease ...

Alzheimer’s has long been considered irreversible, but new research challenges that assumption. Scientists discovered that severe drops in the brain’s energy supply help drive the disease—and ...

New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early ...

The drug is called NU-9, and a team from Northwestern University in the US tested it on mouse models of Alzheimer's disease.

Since its discovery, Alzheimer's disease has been considered irreversible. Consequently, research has focused on preventing ...

An experimental drug developed at Northwestern University has demonstrated further promise as an early intervention for ...

A new drug being developed by scientists at Northwestern University may offer an exciting way to slow down or prevent ...

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from ...

A new drug targets Alzheimer’s at its earliest, most silent stage — before memory loss ever begins. Credit: Shutterstock. A ...